-
Featured Authors
-
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Author Archive: Roy Zwahlen
Roy is a Manager of Intellectual Property and Technology Transfer policy at BIO and the main contributor for Patently Biotech. He is a lawyer by training, with a background in international and national politics. He grew up in the developing world and believes that innovation can and does solve many of the world’s problems. Because of this, his work focuses on creating a worldwide policy environment that fosters innovation in the biotechnology sector to prevent and cure diseases such as HIV, to increase crop yields to feed more people, and to decrease the harmful effects of industry on the environment. Roy spends his free time keeping up with his two kids, a wife that knows everything (no joke), and serving in his church and broader community. Learn more about Roy from his Linkedin Profile.
Latest Posts
Counterfeiting: White House IP Czar Victoria Espinel on working with corporations
White house IP Czar Victoria Espinel spoke at BIO’s 2011 International Convention in a session titled Counterfeiting: How corporations and government can work together. She told the audience that when entering her new assignment she was surprised to find out that counterfeiting was a large problem in the United States and not just abroad. The Administration has increased enforcement in counterfeit medicines as seizures of health related counterfeits have gone up 97% from last year. Read More >
Biotech Patenting and Tech Transfer at 2011 BIO International Convention
The Biotech Patenting and Tech Transfer track has a lot to offer 2011 BIO International Convention Attendees. High level speakers include White House Intellectual Property Enforcement Coordinator Victoria Espinel, European Patent Office Director of Biotechnology Sjoerd Hoekstra, retired Chief Judge of the U.S. Court of Appeals for the Federal Circuit Paul Michel, and former Solicitors General Seth Waxman and Paul Clement to name a few. I am particularly excited about the breadth of the Read More >
Patently BIOtech
Leave a comment
Email This Post
Tags: 2011 BIO International Convention, BIO, biosimilars, Biotech Patenting, collaboration, Collaborative R&D, Compulsory Licensing, Counterfeiting, EPO, Myriad Case, Patent Linkage, Patents in the Supreme Court, Paul Clement, Paul Michel, Seth Waxman, Sjoerd Hoekstra, Tech Transfer, Technology Transfer, Victoria Espinel
Tags: 2011 BIO International Convention, BIO, biosimilars, Biotech Patenting, collaboration, Collaborative R&D, Compulsory Licensing, Counterfeiting, EPO, Myriad Case, Patent Linkage, Patents in the Supreme Court, Paul Clement, Paul Michel, Seth Waxman, Sjoerd Hoekstra, Tech Transfer, Technology Transfer, Victoria Espinel
House Patent Reform Bill, HR 1249, still has the Administration’s and BIO’s support
The White House, Office of Management and Budget, Office of Science and Technology Policy, and the United States Patent and Trademark Office have come out in support of HR 1249 and the Manager’s Amendment to the bill. The only caveat mentioned is that “final legislative action [should] ensure that the US Patent and Trademark Office’s (USPTO’s) fee collections are made fully available to support the nation’s patent and trademark system.” BIO also has come out in Read More >
‘Gene Patents’ Stifle Research?
The Federal Trade Commission has noted that “concern previously centered on the belief that biotechnology patent protection was too strong” and “would actually obstruct commercialization on new products, thereby hindering follow-on innovation. This problem has yet to materialize. The reasons for this are numerous and are often straightforward matters of basic economics. In addition to licensing being widely available, researchers make use of a variety [of] strategies to develop working solutions to the problem of Read More >
Translational Research Forum at BIO International Convention
BIO is hosting a Translation Research Forum at the BIO International Convention. NIH Director Collins keynotes an event that will explore how private, public and academic sectors can leverage meaningful partnerships, highlight emerging best practices, explore risk-sharing at the clinical research stage, and explore ways to bridge the gap in funding and know-how necessary to take university research to the next level. Read the Press Release for more information about panels and speakers. For registration, conference Read More >
